Artwork

Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !

The MDS Sessions: highlights from ASH 2020

59:20
 
Delen
 

Manage episode 290937658 series 2838329
Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone marrow, resulting in ineffective hematopoiesis and cytopenia. Patients typically have a median survival of 0.8 to 8.8 years. Around 30% of patients with MDS will progress to acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) currently represents the only curative option for MDS; however, novel strategies and therapies are under investigation, including personalized medicine approaches and immunotherapies.

In 2020, the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2020) was presented as an all-virtual event due to the COVID-19 pandemic. Despite this, the quality of data and presentations remained exceptionally high and it was not an event to be missed.

In this roundtable discussion, Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center in New Haven, CT, Uwe Platzbecker, MD, of the University of Leipzig in Leipzig, Germany, Andrew Brunner, MD, Massachusetts General Hospital in Boston, MA, and Jacqueline Garcia, MD, Dana-Farber Cancer Institute in Boston, MA, review the hottest topics in the treatment and management of MDS presented at the ASH 2020 Virtual Meeting.

  continue reading

200 afleveringen

Artwork
iconDelen
 
Manage episode 290937658 series 2838329
Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone marrow, resulting in ineffective hematopoiesis and cytopenia. Patients typically have a median survival of 0.8 to 8.8 years. Around 30% of patients with MDS will progress to acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) currently represents the only curative option for MDS; however, novel strategies and therapies are under investigation, including personalized medicine approaches and immunotherapies.

In 2020, the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2020) was presented as an all-virtual event due to the COVID-19 pandemic. Despite this, the quality of data and presentations remained exceptionally high and it was not an event to be missed.

In this roundtable discussion, Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center in New Haven, CT, Uwe Platzbecker, MD, of the University of Leipzig in Leipzig, Germany, Andrew Brunner, MD, Massachusetts General Hospital in Boston, MA, and Jacqueline Garcia, MD, Dana-Farber Cancer Institute in Boston, MA, review the hottest topics in the treatment and management of MDS presented at the ASH 2020 Virtual Meeting.

  continue reading

200 afleveringen

Alle afleveringen

×
 
Loading …

Welkom op Player FM!

Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.

 

Korte handleiding